Preimplantation genetic screening by microarray
- GTR Test IDHelpEach Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. When a laboratory updates a registered test, a new version number is assigned.: GTR000528065.2
- Last updated: 2023-05-22
- Test version history
Clinical testHelpIn the U.S., clinical tests must be performed under CLIA certification. When a lab uses the same methods for a test in both clinical and research settings, the test appears as two separate GTR records. for Autosomal chromosomal disorder
Offered by Pittsburgh Cytogenetics Laboratory
Overview
Test name
HelpThe name the laboratory assigns the test. Used as the default title of the page specific to the test.Preimplantation genetic screening by microarray (PGS microarray)
This is a clinical test intended for HelpPurposes or indications for the test. Lab-provided.: Pre-implantation genetic diagnosis, Screening
Click Indication tab for more information.
For more information, please contact the laboratory directly.
Order URL HelpLink to the laboratory webpage with information about how to order this test. Please note that clicking on this link will open a new tab in your internet browser.: http://www.upmc.com/locations/hospitals/magee/services/center-for-fertility-and-reproductive-endocrinology
Methodology
HelpThe assay's major method category (biochemical, cytogenetic or molecular genetics); method category (i.e. enzyme assay, chromosome breakage studies, targeted mutation analysis); methodology (i.e. the name of the method used) and instruments used when performing this test.- Molecular Genetics
- DDeletion/duplication analysis
- Microarray
- Agilent SureSelect
- Agilent SurePrint G3 Human CGH Microarray Kit, 2x400K
Reproductive decision-making
- Two different microarray technologies for preimplantation genetic diagnosis and screening, due to reciprocal translocation imbalances, demonstrate equivalent euploidy and clinical pregnancy rates. - PubMed ID: 24771116
Clinical validity
HelpHow consistently and accurately the test detects or predicts the intermediate or final outcomes of interest. Lab-provided.Not provided
Testing strategy
HelpThe lab's suggested sequence of ordering tests based on clinical scenarios. It may include information on: reflex testing including each test component, and scenarios which prompt additional components of testing; whether lab communicates interim results or automatically proceeds to further analyses; and if any components are performed in another laboratory.Standard In vitro fertilization and embryo transfer (IVF-ET) involves controlled ovarian hyperstimulation to obtain multiple (6-12) mature oocytes, in vitro fertilization, and culturing to the blastocyst stage (70-120 cells) by day 5 after fertilization. These procedures can be performed at the Center for Fertility and Reproductive Endocrinology at Magee-Womens Hospital​. In average 40% of all IVF embryos appear normal, but still have a whole chromosome abnormality. The ultimate goal of IVF-ET is to identify chromosomally normal embryos by preimplantation genetic screening (PGS) and to perform a single embryo transfer. PGS involves removing 4-6 placental cells from normal appearing blastocysts. The biopsy samples are then subject to DNA amplification and then microarray comparative genomic hybridization to determine if the blastocyst is euploid or aneuploid. Transfer of a single chromosomally normal embryo improves the odds that in vitro fertilization procedure will result in a live born child and reduces the risk of complications associated with multi-fetal pregnancy. 000 For more information, please contact the laboratory directly.
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.